Targeted therapy- NSCLC

Question 1

Erlotinib

Answer 1

EGFR

1st line or later

Question 2

Gefitinib

Answer 2

EGFR

1st line or later

Question 3

Afatinib

Answer 3

EGFR, Her2, Her4

1st line or later

Question 4

Osimertinib

Answer 4

EGFR, T790M
1st line or later
Improved PFS compared to gefitinib or erlotinib
Preferred for CNS penetration

Question 5

Capmatinib

Answer 5

Met exon 14 skipping mutation

1st line or later

Question 6

Crizotinib

Answer 6

ALK translocation
ROS-1 rearrangement
Met exon 14 skipping mutation
No longer recommended 1st line for ALK based on improved PFS/OS with alectinib

Question 7

Ceritinib

Answer 7

ALK translocation, V1180L

1st line or later

Question 8

Alectinib

Answer 8

ALK translocation
Preferred 1st line agent
Preferred for CNS penetration

Question 9

Brigatinib

Answer 9

ALK translocation, V1180L
1st line or later
Improved PFS over crizotinib

Question 10

Lorlatinib

Answer 10

ALK translocation
1st line or later

ROS1 rearrangement
2nd line or later

Question 11

Entrectanib

Answer 11

NTRK fusion
ROS-1 rearrangement
High CNS penetration

Question 12

Larotrectanib

Answer 12

NTRK fusion

Question 13

Selpercatinib

Answer 13

RET fusion